Michel Marty

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Michel Marty, Francesco Cognetti, D Maraninchi et al. · IRIS UNIMORE (University of Modena and Reggio Emilia) · 2005 · 1.6K citations · Full text

Comparison of the 5-Hydroxytryptamine₃(Serotonin) Antagonist Ondansetron (Gr 38032F) with High-Dose Metoclopramide in the Control of Cisplatin-Induced Emesis

Michel Marty, P Pouillart, Jean Pierre Droz et al. · New England Journal of Medicine · 1990 · 411 citations

Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial

Jean‐Yves Pierga, François‐Clément Bidard, Claire Mathiot et al. · Clinical Cancer Research · 2008 · 370 citations

Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy

P Bertheau, François Plassa, Marc Espié et al. · The Lancet · 2002 · 161 citations

Breast Oncology, Medicine, Pathology +8

Distinct <i>tumor protein p53</i> mutants in breast cancer subgroups

Anne Dumay, Jean‐Paul Feugeas, Evelyne Wittmer et al. · International Journal of Cancer · 2012 · 113 citations · Full text

Breast Oncology, Endocrine-related Cancer, Tumor Heterogeneity +15